The next time you walk into a Sprint store you could be greeted by their newest employee, the humanoid robot "Pepper." Pepper uses machine learning and artificial intelligence to greet customers and work with them throughout their Sprint store experience. Pepper is already in some stores across America.
Jan Geldmacher is the Business President at Sprint. He joins Cheddar to explain how Pepper is helping to lead the industry in robot artificial intelligence. Pepper can recognize facial expressions and react to customers accordingly.
Geldmacher also explains how 5g will revolutionize the way we live and work. The biggest differences between 4g and 5g for Geldmacher are speed and latency.
When asked what's next for Sprint, Geldmacher explained that this year they will be focusing on the development of their IOT ecosystem.
Australia’s Great Barrier Reef is spawning in an explosion of color as the World Heritage-listed natural wonder recovers from life-threatening coral bleaching episodes.
Climate change that may have contributed to a lobster boom in Maine could soon lead to a bust. Chloe Aiello reports.
Good Morning America co-host Michael Strahan will be among the crew on Blue Origin’s next flight to space.
President Joe Biden is ordering a record-setting 50 million barrels of oil released from America's strategic reserve to help bring down energy costs.
All the news you Need2Know for Tuesday, November 23, 2021.
The U.S. is moving to open up COVID-19 booster shots to all adults, letting them choose another dose of either the Pfizer or Moderna vaccine.
U.S. health officials say an estimated 100,000 Americans died of drug overdoses in one year. That's a total the nation has never seen.
Russian officials on Tuesday rejected accusations that they endangered astronauts aboard the International Space Station by conducting a weapons test that created more than 1,500 pieces of space junk.
Austria has taken what its leader called the “dramatic” step of implementing a nationwide lockdown for unvaccinated people who haven’t recently had COVID-19.
Pfizer Inc. said Friday that its experimental antiviral pill for COVID-19 cut rates of hospitalization and death by nearly 90% in high-risk adults, as the drugmaker joins the race to bring the first easy-to-use medication against the coronavirus to the U.S. market.
